CFDE Data Portal | Search SIGLECL1

	Label	Description
	SIGLECL1 associations Collection (Entity type)	Associations for SIGLECL1_associations
	SIGLECL1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	SIGLECL1 Gene (Entity type)	ENSG00000179213 - SIGLEC family like 1
	GSE182680,GSE182683 7 V 3 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE120612 6 V 5 ETOPOSIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE140322 0 V 2 IMATINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 4 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE182680 GSE182683 dexamethasone 7 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE185519 3 V 7 GILTERITINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE182680,GSE182683 7 V 13 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

SIGLECL1 associations

Associations for SIGLECL1_associations

SIGLECL1 associations.tsv

A file from IDG as part of the Harmonizome project

SIGLECL1

ENSG00000179213 - SIGLEC family like 1

GSE182680,GSE182683 7 V 3 DEXAMETHASONE HUMAN UP

A Gene Set from LINCS

GSE120612 6 V 5 ETOPOSIDE HUMAN DN

A Gene Set from LINCS

GSE140322 0 V 2 IMATINIB HUMAN DN

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 4 v 0 human dn

A Gene Set from LINCS

GSE182680 GSE182683 dexamethasone 7 v 11 human up

A Gene Set from LINCS

GSE185519 3 V 7 GILTERITINIB HUMAN DN

A Gene Set from LINCS

GSE182680,GSE182683 7 V 13 DEXAMETHASONE HUMAN UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.